GemPharmatech

GemPharmatech is thrilled to be heading to the 17th Chinese American Diabetes Association (#CADA) Annual Meeting this June! We’ll be bringing our latest advances in cutting-edge preclinical models, supporting researchers working to unlock new insights in #diabetes and #metabolicdisease. Connect with our team member Dora Li and Coco Zhang onsite to explore how our tailored solutions can accelerate your research from concept to discovery. 📍 Join us in New Orleans—we’d love to meet you and discuss how we can help drive your next breakthrough. #GemPharmatech #CADA2026 #DiabetesResearch #MetabolicDisease #PreclinicalModels

🎉 Just wrapped a productive seminar at CHA Bio Complex in Gyeonggi-do, South Korea! We appreciate everyone who joined us—your engagement and thoughtful questions made all the difference. In this seminar, our scientists, Dr. Shuxin Xu, Dr. Jianming Xu, and Dr. Wen Zeng shared deep insights into how innovative #mousemodels and comprehensive #preclinical approaches are accelerating translational drug development across oncology, #autoimmune disease, and #metabolic disease. Key topics included: ✔️ #Oncology drug discovery strategies ✔️ Phenotype-driven #asthma models ✔️ Critical considerations for evaluating #weightloss drugs We also had fantastic discussions with the local research community at CHA Bio Complex. 📌 Missed the session? No worries. Reach out to us at globalservice@gempharmatech.com – we'd be happy to share key insights and discuss how we can support your next preclinical program. Looking forward to building new partnerships and continuing to advance discovery together. #GemPharmatech #Biotech #Pharma #Innovation #PreclinicalResearch #MouseModels #LifeSciences #SouthKorea #CHABioComplex #Seminar #DrugDevelopment

CAR-T therapy has reshaped the treatment landscape for hematological malignancies, but ex vivo approaches still face challenges in manufacturing complexity, cost, and accessibility. In our latest blog, we explored how in vivo CAR-T is emerging as a next-generation strategy — and why robust preclinical evaluation is critical for clinical translation. We discussed:  ✅ Differences between conventional and in vivo CAR-T approaches  ✅ Evaluation strategies for viral and LNP-based delivery systems  ✅ Role of humanized mouse models in efficacy, safety, and toxicity studies  ✅ Advantages of NCG-MHC-dKO and huHSC-NCG models  ✅ How PBMC donor screening and pre-established cohorts accelerate timelines 👉 Read the full blog to learn more: https://lnkd.in/gGERe2rZ #GemPharmatech #CART #invivoCART #CellTherapy #Immunotherapy #GeneTherapy #DrugDevelopment #PreclinicalResearch #HumanizedMouseModels 

Last week at the #ASGCT2026 Annual Meeting, we had a great time connecting with the gene therapy and immuno-oncology community. Thank you to everyone who stopped by our booth, attended our poster sessions, and engaged in insightful scientific discussions! We presented two posters on-site, both of which are now available for download. 1️⃣ In vivo CAR-T therapy platform  We demonstrated efficient in vivo generation of CD19 CAR-T cells using both lentiviral vectors and LNP-based delivery in a humanized NCG-MHC-dKO model with delayed GVHD, enabling an extended longitudinal evaluation window. Both modalities achieved strong tumor control in Nalm-6 xenograft models, along with robust in vivo CAR-T expansion. 🔗 Download: https://lnkd.in/gfwGhxGi 2️⃣ Integrated mRNA cancer vaccine platform  We developed a modular preclinical platform combining in vitro immune profiling with HLA-humanized in vivo validation models. In PDX settings, TA-1 (mRNA vaccine) and anti–PD-1 monotherapy each showed clear tumor growth inhibition, with combination treatment delivering enhanced efficacy. These findings support the preclinical evaluation of next-generation mRNA cancer vaccines in human-relevant immune contexts. 🔗 Download: https://lnkd.in/gDa9x4WE We appreciate all the engagement at ASGCT 2026 and look forward to continuing the conversation as we advance these programs. 📩 Contact us: sales@gempharmatech.com #GemPharmatech #ASGCT #GeneTherapy #CAR_T #InVivoCAR_T #mRNA #CancerVaccine #ImmunoOncology #CellTherapy #TranslationalResearch #Biotech #DrugDevelopment #PreclinicalResearch

#Asthma remains one of the most complex chronic inflammatory disorders of the airways. In our latest blog, we explore why mechanism-driven selection of mouse models is becoming essential for translational asthma research, especially as the field moves beyond the traditional eosinophilic (T2) paradigm. Key insights:  ✔️ T2 and non-T2 asthma models respond very differently to therapies  ✔️ Steroid-resistant, neutrophilic models better reflect major unmet clinical needs  ✔️ Model-dependent efficacy can determine translational success or failure  ✔️ Head-to-head data reveal why therapies like anti-IL-4RA succeed in some settings but fail in others We also share #GemPharmatech’s asthma model matrix designed to support MoA-driven drug discovery and improve clinical relevance from the start. 👉 Click the link to read the full blog: https://lnkd.in/gtk-364z #AsthmaResearch #DrugDiscovery #TranslationalResearch #Immunology #Inflammation #RespiratoryDisease #PreclinicalResearch #Biologics #MouseModels #Pharma #Biotech

🚀 New insights now available: R&D trends shaping the future of neurological disease research are here. While #neuroscience research continues to advance across biologics, gene therapies, and cell-based approaches, translating early-stage discoveries into reliable therapeutic outcomes remains a key challenge for the field. In collaboration with Inpart, this report reviews current R&D trends and emerging innovations across #neurologicaldiseases, with a focus on areas showing increasing engagement within the early-stage research landscape. We also include a brief spotlight on next-generation neuroscience platforms designed to support more predictive and #translationalresearch models. For those working in neuroscience, drug discovery, or translational research, the report may offer useful context on where the field is heading. 📥 Download here: https://lnkd.in/gSpG-s_C #Neuroscience #Neurology #DrugDiscovery #Biotech #GeneTherapy #CellTherapy #AlzheimersDisease

At #GemPharmatech, we develop physiologically relevant and translational animal models to support advanced #hypertension research, a disease highly prevelant in cardiovascular diseases. To better recapitulate human disease mechanisms, we have established knock-in humanized models targeting the renin–angiotensin–aldosterone system (#RAAS), a central regulator of blood pressure homeostasis. 🔬 Hypertension Models Induced via RAAS Activation ◾ 𝗕𝟲-𝗥𝗼𝘀𝗮𝟮𝟲-𝗵𝗔𝗚𝗧 (𝗧𝟬𝟱𝟴𝟯𝟱𝟭): https://lnkd.in/guj2kA3K ◾ 𝗕𝟲-𝗵𝗔𝗚𝗧 / 𝗛𝟭𝟭-𝗵𝗥𝗘𝗡 (𝗧𝟬𝟱𝟵𝟴𝟬𝟲): https://lnkd.in/gwjEwSyZ   These humanized models feature full replacement of the human AGT genomic sequence (CDS, 5’ UTR, 3’ UTR), ensuring high physiological relevance and improved translational predictability. 🧬 Key Advantages • Humanized gene design for enhanced clinical relevance • Robust, inducible hypertension phenotypes • Enables quantitative blood pressure assessment, addressing a key limitation of many conventional models • Strong validation supported by extensive nucleic acid therapeutic studies • IND-enabling experience in hypertension and related cardiovascular complications   📌 Please refer to the image below for detailed model information.   Beyond hypertension, GemPharmatech offers a comprehensive #cardiovascular research platform spanning disease modeling, integrated phenotypic analysis, and #preclinical efficacy evaluation across multiple therapeutic modalities—supporting the full workflow from target validation to preclinical development. 🔬 Cardiovascular Mouse Models Well-characterized models covering hypertension, #atherosclerosis, #heartfailure, #arrhythmia, and rare cardiovascular diseases. 📊 Integrated Phenotypic Analysis Advanced ECG, echocardiography, and hemodynamic monitoring for comprehensive cardiovascular assessment. 💊 Drug Screening & Efficacy Evaluation Preclinical testing solutions for #smallmolecules, #antibodies, gene therapies, and RNA-based therapeutics. We aim to accelerate the translation of innovative cardiovascular therapies from discovery to preclinical development. 🔗 Learn more about our cardiovascular pipeline: https://lnkd.in/gdTeKdp3 #Hypertension #CardiovascularResearch #DrugDiscovery #PreclinicalResearch #Biotech #GeneTherapy #RNAtherapeutics #TranslationalResearch

We’re excited to attend the 49th Workshop of the Korean Society of Nonclinical Study (#KSNS) on May 29 at the Suwon Convention Center in Gyeonggi-do, South Korea! Visit GemPharmatech at Booth #24 and connect with our team: Shinae Hwang, Jason Fang Ph.D., Eunha Shim and Aileen Wu. Come explore how we can help accelerate your preclinical research with: 🔬 Tailored preclinical solutions designed around your unique R&D needs 🐭 Access to 25,000+ mouse strains for precise genetic matching We’ll also have exclusive swag waiting for visitors at the booth 🎁 Looking forward to great conversations and new collaborations in Suwon. See you there! #KSNS2026 #GemPharmatech #PreclinicalResearch #MouseModels #DrugDiscovery #Biotechnology #LifeScience #Innovation

We’re ready to kick off Day 2 at #ASGCT2026 in Boston! A big thank you to everyone who stopped by Booth #1430 yesterday. We had some great discussions throughout the day. 🧬 Poster presentation – (2044) Evaluating in vivo CAR-T efficacy in a humanized NCG-MHC-DKO mouse model with delayed GVHD 🕔 5:00–6:30 PM ET 🎤 Presenter: Dr. Yang Yu Attend our poster session or visit Booth #1430 today to learn how our humanized NCG-MHC-DKO model, featuring delayed GVHD, supports in vivo CAR-T efficacy studies. Looking forward to more conversations on translational models for immuno-oncology and advanced preclinical research! #GemPharmatech #ASGCT2026 #GeneTherapy #CellTherapy #ImmunoOncology #CART #CancerVaccines #PreclinicalResearch

We’re excited to share two posters GemPharmatech will present at #ASGCT2026 (Boston | May 12–14), showcasing advances in predictive in vivo models for immuno-oncology. Visit us at Booth #1430 to meet our team: Yang Yu, Keiji Furuuchi, PhD, Pei Luo, and Taylor Bateman. 📌 Poster Highlights 🧬 (2044) In Vivo CAR-T Therapy Evaluating in vivo CAR-T efficacy in a humanized NCG-MHC-DKO mouse model with delayed GVHD 🗓 May 13 | 5:00–6:30 PM ET 🧬 (3242) Cancer Vaccines Preclinical assessment of cancer vaccines: bridging in vivo efficacy with in vitro immune monitoring 🗓 May 14 | 5:00–6:30 PM ET These studies support more translational, human-relevant approaches to gene and cell therapy research. If you’re attending ASGCT, we’d love to connect! #GemPharmatech #ASGCT #GeneTherapy #CellTherapy #ImmunoOncology #CART #CancerVaccines #Biotech #PreclinicalResearch